TMF1

Across TCGA pan-cancer cohorts, TMF1 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TMF1 data layer compared with 25 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher TMF1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TMF1 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LUAD, UCEC, and STAD are the cancer types where TMF1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.305	0.816	<.001	27	view →
UCEC	DFS	Median	II,III,IV	0.933	0.303	.009	26	view →
STAD	DFS	Median	All	0.314	0.634	.027	22	view →
UCS	OS	Median	All	0.185	0.686	.034	6	view →
LIHC	OS	Median	All	0.105	0.774	.002	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TMF1–LUAD (OS)

Open the LUAD breakdown →